PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
3111454-4	1987	Apo B and apo A-I had significant positive correlations with the content of chondroitin sulphates A + C (CS A + C), which comprised 35% to 47% of the aortic GAG.	Chondroitin Sulfates	76-97	apolipoprotein B	Homo sapiens	0-5	
24055620-1	2013	A rigorous processing of adsorption data from quartz crystal microbalance technology was successfully combined with the data obtained by partial filling affinity capillary electrophoresis and molecular dynamics for the clarification of the temperature effect on the interaction of a major glycosaminoglycan chain chondroitin-6-sulfate (C6S) of proteoglycans with low-density lipoprotein (LDL) and with a peptide fragment of apolipoprotein B-100 (residues 3359-3377 of LDL, PPBS).	Chondroitin Sulfates	313-334	apolipoprotein B	Homo sapiens	424-444	
31375727-4	2019	The first disk with C6S was targeted to remove chylomicrons, very-low-density lipoprotein (VLDL) particles, and their remnants including intermediate-density lipoprotein (IDL) particles, thus allowing the remaining major lipoprotein species, i.e. LDL, lipoprotein(a) (Lp(a)), and high-density lipoprotein (HDL) to flow to the anti-apoB-100 disk.	Chondroitin Sulfates	20-23	apolipoprotein B	Homo sapiens	331-339	
25290812-4	2014	In terms of suppression of gene expression in vivo, apolipoprotein B (ApoB) mRNA in the liver and low-density-lipoprotein (LDL) and very low-density-lipoprotein (VLDL) cholesterol level in serum were reduced at 48 h after single sequential injection of PGA or CS plus cationic lipoplex of cholesterol-modified ApoB siRNA.	Chondroitin Sulfates	260-262	apolipoprotein B	Homo sapiens	52-68	
25290812-4	2014	In terms of suppression of gene expression in vivo, apolipoprotein B (ApoB) mRNA in the liver and low-density-lipoprotein (LDL) and very low-density-lipoprotein (VLDL) cholesterol level in serum were reduced at 48 h after single sequential injection of PGA or CS plus cationic lipoplex of cholesterol-modified ApoB siRNA.	Chondroitin Sulfates	260-262	apolipoprotein B	Homo sapiens	70-74	
7706380-3	1995	Biol., 28A:176-180) and the protein moiety of low density lipoproteins (LDL; apo B-100) via a similar sequence to chondroitin sulfate (Camejo et al., 1988, Arteriosclerosis Thromb., 8:368-377).	Chondroitin Sulfates	114-133	apolipoprotein B	Homo sapiens	77-86	
21651232-1	2011	Two different experimental approaches were used for obtaining a comprehensive view and understanding of the interactions between apolipoprotein B-100 (ApoB-100) of low-density lipoprotein and apolipoprotein E (ApoE) of high-density lipoprotein and chondroitin-6-sulfate (C6S) of arterial proteoglycan.	Chondroitin Sulfates	248-269	apolipoprotein B	Homo sapiens	151-159	
21651232-1	2011	Two different experimental approaches were used for obtaining a comprehensive view and understanding of the interactions between apolipoprotein B-100 (ApoB-100) of low-density lipoprotein and apolipoprotein E (ApoE) of high-density lipoprotein and chondroitin-6-sulfate (C6S) of arterial proteoglycan.	Chondroitin Sulfates	271-274	apolipoprotein B	Homo sapiens	129-149	
21651232-1	2011	Two different experimental approaches were used for obtaining a comprehensive view and understanding of the interactions between apolipoprotein B-100 (ApoB-100) of low-density lipoprotein and apolipoprotein E (ApoE) of high-density lipoprotein and chondroitin-6-sulfate (C6S) of arterial proteoglycan.	Chondroitin Sulfates	271-274	apolipoprotein B	Homo sapiens	151-159	
7929840-6	1994	The addition of exogenous chondroitin sulfate or apolipoprotein B inhibited the binding of PG-M-CSF to LDL in a dose-dependent manner, indicating that the interaction between PG-M-CSF and LDL was mediated by the binding of the chondroitin sulfate chain of PG-M-CSF to LDL apolipoprotein B.	Chondroitin Sulfates	26-45	apolipoprotein B	Homo sapiens	272-288	
7929840-6	1994	The addition of exogenous chondroitin sulfate or apolipoprotein B inhibited the binding of PG-M-CSF to LDL in a dose-dependent manner, indicating that the interaction between PG-M-CSF and LDL was mediated by the binding of the chondroitin sulfate chain of PG-M-CSF to LDL apolipoprotein B.	Chondroitin Sulfates	227-246	apolipoprotein B	Homo sapiens	49-65	
1907203-0	1991	Molecular parameters that control the association of low density lipoprotein apo B-100 with chondroitin sulphate.	Chondroitin Sulfates	92-112	apolipoprotein B	Homo sapiens	77-86	
1907203-4	1991	Results from earlier studies suggest that surface located segments of apo B-100 are responsible for the interaction of LDL with heparin and chondroitin sulphate-rich arterial proteoglycans.	Chondroitin Sulfates	140-160	apolipoprotein B	Homo sapiens	70-79	
2029496-5	1991	We confirmed the work of others that it is the apolipoprotein B component and, at least in part, a heparin-binding domain of LDL that are responsible for binding chondroitin sulfate/dermatan sulfate proteoglycans.	Chondroitin Sulfates	162-181	apolipoprotein B	Homo sapiens	47-63	
8439543-0	1993	Binding of a synthetic apolipoprotein B-100 peptide and peptide analogues to chondroitin 6-sulfate: effects of the lipid environment.	Chondroitin Sulfates	77-98	apolipoprotein B	Homo sapiens	23-43